Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A

NCT01401257 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Charcot-Marie-Tooth Disease
Hereditary Neuropathy With Liability to Pressure Palsies
Genetic Disorders

Interventions

DRUG: PXT3003 Low dose
DRUG: PXT3003 Intermediate Dose
DRUG: PXT3003 High Dose
OTHER: Placebo

Sponsor

Pharnext S.C.A.